**11. Conclusion**

Until now, there is no consensus on which miRNA could be the best target for therapy. To alter the cell homeostasis of miRNAs, more than one change is needed for their biogenesis. Similar to previous reports, miRNA can have several target mRNAs and one mRNA can be regulated by different microRNAs. ALS research provides an example of NEFL synthesis alteration, which can be regulated by miR-b2403, miR-b1336, miR-146a, miR-524-5p, and miR-582-3p. Probably, for the development of diseases, the coincidence of more than one dysregulation is necessary, or the accumulative alteration of various changes in the transcriptome, to induce neuron cell death. On the other hand, the dysregulation of miRNAs on neighbor cells partic‐ ipates in ALS pathology, where microglia cells, lymphocytes, Schwann cells, and muscle cells show a dysregulation in the miRNA transcript. Further, miRNAs also participate in neuron death. Nevertheless, research on miRNAs involves looking at miRNAs from the perspective of biomarkers. Moreover, the systematic comparative analysis of their profile between healthy people and ALS patients provides information on which pathways can be suggested as possible targets for directed therapy. In addition, the analysis also provides an opportunity to know more about the development of this disease, metabolic pathways altered, and cells involved in ALS pathology.
